NRBO vs. RLAY
Compare and contrast key facts about NeuroBo Pharmaceuticals, Inc. (NRBO) and Relay Therapeutics, Inc. (RLAY).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: NRBO or RLAY.
Key characteristics
| NRBO | RLAY | |
|---|---|---|
| YTD Return | -8.03% | -31.15% |
| 1Y Return | -19.66% | -17.52% |
| 3Y Return (Ann) | -85.14% | -41.18% |
| Sharpe Ratio | -0.19 | -0.18 |
| Daily Std Dev | 101.77% | 85.91% |
| Max Drawdown | -100.00% | -90.41% |
| Current Drawdown | -100.00% | -87.68% |
Fundamentals
| NRBO | RLAY | |
|---|---|---|
| Market Cap | $28.86M | $1.23B |
| EPS | -$4.99 | -$2.52 |
| Total Revenue (TTM) | $4.00K | $35.21M |
| Gross Profit (TTM) | -$11.00K | $29.71M |
| EBITDA (TTM) | -$26.51M | -$370.10M |
Correlation
The correlation between NRBO and RLAY is 0.18, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
NRBO vs. RLAY - Performance Comparison
In the year-to-date period, NRBO achieves a -8.03% return, which is significantly higher than RLAY's -31.15% return. The chart below displays the growth of a $10,000 investment in both assets, with all prices adjusted for splits and dividends.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
NRBO vs. RLAY - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for NeuroBo Pharmaceuticals, Inc. (NRBO) and Relay Therapeutics, Inc. (RLAY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
NRBO vs. RLAY - Dividend Comparison
Neither NRBO nor RLAY has paid dividends to shareholders.
Drawdowns
NRBO vs. RLAY - Drawdown Comparison
The maximum NRBO drawdown since its inception was -100.00%, which is greater than RLAY's maximum drawdown of -90.41%. Use the drawdown chart below to compare losses from any high point for NRBO and RLAY. For additional features, visit the drawdowns tool.
Volatility
NRBO vs. RLAY - Volatility Comparison
The current volatility for NeuroBo Pharmaceuticals, Inc. (NRBO) is 22.43%, while Relay Therapeutics, Inc. (RLAY) has a volatility of 48.60%. This indicates that NRBO experiences smaller price fluctuations and is considered to be less risky than RLAY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
NRBO vs. RLAY - Financials Comparison
This section allows you to compare key financial metrics between NeuroBo Pharmaceuticals, Inc. and Relay Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities